EHA 2016: Can biosimilars ensure access to drugs for everyone?

Robin Foà, MD from the Sapienza University, Rome, Italy discusses whether biosimilars may help increase the access to novel drugs. Prof. Foà points out that the saving might be around 30% of the original drug cost, which means that biosimilars would not necessarily make novel drugs accessible everywhere. Biosimilars are a step forward but they will not solve the problem according to Prof. Foà.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.